Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma

Cancer

Volumn 94, Issue 11, 2002, Pages 2914-2922

  Nisman, Benjamin ^a   Barak, Vivian ^a   Shapiro, Amos ^a   Golijanin, Dragan ^a   Peretz, Tamar ^a   Pode, Dov ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Bacillus Calmette Guerin; Bladder carcinoma; Urine CYFRA 21 1; Urine cytology

Indexed keywords

CREATININE; CYTOKERATIN 19 FRAGMENT;

ADULT; AGED; ARTICLE; BCG VACCINATION; BLADDER CARCINOMA; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CARCINOMA IN SITU; CENTRIFUGATION; CONTROLLED STUDY; CYSTOSCOPY; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; EARLY DIAGNOSIS; HEMATURIA; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URINE CYTOLOGY; URINE LEVEL; UROLITHIASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; FEMALE; HEMATURIA; HUMANS; IMMUNOASSAY; KERATINS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0036604272     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10565     Document Type: Article

References (34)

1. Cancer statistics, 2001
2. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentation
3. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients
4. Cytologic techniques as a diagnostic and prognostic tool in urologic cancer
5. Urine based markers of urological malignancy
6. Cytokeratin shedding in urine: A biological marker for bladder cancer?
7. Antigenicity of pooled human malignant and normal tissues by cyto-immunological technique: Presence of an insoluble, heat-labile tumor antigen
8. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells
9. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: Re-evaluation of a human tumor marker
10. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder
11. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma
12. Lung cancer-associated keratin 19-fragments: Development and biochemical characterization of the new serum assay Enzymun test® CYFRA 21-1
13. The biochemistry of CYFRA 21-1 and other cytokeratin tests
14. Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer
15. Cytokeratin-19 fragment (CYFRA 21-1) in bladder cancer
16. Standardization of assay for cytokeratin-related tumor marker CYFRA 21.1 in urine samples
17. CYFRA 21-1 quantity measurement in the urine of patients with carcinoma of the urinary bladder and tract
18. Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer
19. The clinical value of CYFRA 21-1 in bladder cancer patients: Egyptian experience
20. New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: Analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer
21. The meaning and use of an area below the receiver operating characteristic curves
22. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder
23. Comparison of screening methods in the detection of bladder cancer
24. Immunocyte: A new tool for detecting transitional cell cancer of the urinary tract
25. Urinary hyaluronic acid and hyaluronidase markers for bladder cancer detection and evaluation of grade
26. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer
27. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder
28. Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer
29. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer
30. Urothelial tumors of the urinary tract
31. Bladder tumor control by abdominal ultrasound and urine cytology